<DOC>
	<DOCNO>NCT02652819</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled study treatment anemia subject CKD dialysis , treatment 52 week .</brief_summary>
	<brief_title>FG-4592 Treatment Anemia Subjects With Chronic Kidney Disease Not Dialysis</brief_title>
	<detailed_description>This randomize , multicenter , double-blind , placebo-controlled study treatment anemia subject CKD dialysis . Eligible subject randomize FG-4592 placebo ratio 2:1 . The primary endpoint change Hb baseline average level Weeks 7 9 inclusive .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Ages 18 75 year 2 . Subject voluntarily sign date informed consent form ( ICF ) , approve Ethics Committee ( EC ) , nature study explain subject opportunity ask question . 3 . Diagnosis chronic kidney disease , Kidney Disease Outcomes Quality Initiative ( KDOQI ) Stage 3 , 4 , 5 , receive dialysis ; estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m2 estimate use abbreviated 4variable Modification Diet Renal Disease ( MDRD ) equation . 4 . No use erythropoiesisstimulating agent ( ESA ) least 5 week randomization . 5 . Mean two recent Hb value Screening Period obtain least 6 day apart must ≥7.0 g/dL &lt; 10 g/dL . 6 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤1.5 x upper limit normal ( ULN ) , normal total bilirubin screen visit ( base central laboratory result ) . 7 . Body weight : 40 100 kg inclusive . 8 . Subjects agree start take new Traditional Chinese Medicine ( TCM ) anemia change dose , schedule , brand prescreening TCM anemia begin Screening Period end Followup Period without approval FibroGen China Medical Monitor . 1 . Any clinically significant infection evidence active underlying infection . 2 . Positive following : human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus antibody ( antiHCV Ab ) . 3 . Chronic liver disease . 4 . New York Heart Association Class III IV congestive heart failure . 5 . Myocardial infarction , acute coronary syndrome , stroke , seizure , thromboembolic event ( eg , deep venous thrombosis pulmonary embolism ) within 52 week prior Day 1 . 6 . Uncontrolled hypertension opinion investigator ( eg , require change antihypertensive medication within 2 week prior randomization ) . 7 . Diagnosis suspicion ( eg , complex kidney cyst Bosniak Category II high ) renal cell carcinoma show screen renal ultrasound . 8 . History malignancy except follow : cancer determine cured remission ≥5 year , curatively resect basal cell squamous cell skin cancer , situ cancer site . 9 . Chronic inflammatory disease glomerulonephritis could impact erythropoiesis ( eg , systemic lupus erythematosis [ SLE ] , rheumatoid arthritis , celiac disease ) . 10 . Clinically significant gastrointestinal bleeding . 11 . Known history myelodysplastic syndrome , multiple myeloma , hereditary hematologic disease thalassemia , sickle cell anemia , pure red cell aplasia , know cause anemia CKD , hemosiderosis , hemochromatosis , know coagulation disorder , hypercoagulable condition . 12 . Any prior functioning organ transplant schedule organ transplantation , anephric . 13 . Anticipated elective surgery could lead significant blood loss study period . 14 . Anticipated use dapsone acetaminophen ( paracetamol ) &gt; 2.0 g/day , &gt; 500 mg per dose repeat every 6 hour 3 day . 15 . Serum albumin &lt; 2.5 g/dL . 16 . Androgen , deferoxamine , deferiprone , deferasirox therapy within 12 week prior Day 1 . 17 . Life expectancy &lt; 12 month . 18 . Blood transfusion within 12 week prior Day 1 anticipate need transfusion . 19 . IV iron supplement Screening Period /or unwilling withhold IV iron . 20 . Immune suppressive systematic steroid treatment within 12 week prior Day 1 . 21 . History alcohol drug abuse within past 2 year inability avoid consumption &gt; 3 alcoholic beverage per day . 22 . Prior treatment FG4592 hypoxiainducible factor prolyl hydroxylase inhibitor ( HIFPHI ) . 23 . Use investigational medication treatment , participation investigational interventional study , carryover effect investigational treatment expect study . 24 . Women pregnant breastfeeding . 25 . Women childbearing potential men sexual partner child bear potential use adequate contraception . 26 . Any medical condition , opinion investigator , may pose safety risk subject study , may confound efficacy safety assessment , may interfere study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>